Filing Details
- Accession Number:
- 0001209191-17-014829
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-02-27 16:54:47
- Reporting Period:
- 2017-02-23
- Filing Date:
- 2017-02-27
- Accepted Time:
- 2017-02-27 16:54:47
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
879169 | Incyte Corp | INCY | Services-Commercial Physical & Biological Research (8731) | 943136539 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1236927 | A Paul Friedman | 1801 Augustine Cut-Off Wilmington DE 19803 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-02-23 | 50,000 | $18.32 | 347,518 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-02-23 | 50,000 | $120.32 | 297,518 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2017-02-23 | 50,000 | $0.00 | 50,000 | $18.32 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
144,542 | 2020-02-08 | No | 4 | M | Direct |
Footnotes
- Represents weighted average sale price. Actual sale prices ranged from $120.00 - $120.64.
- Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated.
- Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.